GEN Exclusives

More »

GEN News Highlights

More »
May 3, 2007

Sunesis to Use CyDex Technology for Formulation of Anticancer Candidate

  • CyDex licensed its Captisol® enabling technology to Sunesis Pharmaceuticals for formulation of a selective aurora kinase inhibitor with antitumor activity across a number of nonclinical human cancer models.

    CyDex states that this technology improves water solubility, bioavailability, and complexation characteristics of insoluble and/or unstable drugs.

    Sunesis will use Captisol for the formulation of SNS-314, a selective small molecule inhibitor of aurora kinases that potently inhibits proliferation of a wide panel of human cancer cell lines. An IND has been submitted for SNS-314, and a Phase I trial for the treatment of patients with solid tumors is planned to begin in the second quarter of 2007.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?